{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003661","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2025-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.111754+00:00","generated_at":"2026-05-19T23:57:23.483043+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corvus soquelitinib Phase 1 atopic dermatitis data show statistically significant EASI improvement vs placebo","bullets":["Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).","Cohort 3 (200 mg BID) achieved 64.8% mean EASI reduction vs 34.4% for placebo.","In cohort 3, 50% of evaluable patients (4/8) had a ≥4-point itch reduction (PP-NRS) at day 28.","No safety signals; soquelitinib well tolerated with no DLTs and only one grade 1 AE (nausea).","Extension cohort (200 mg BID, 8-week treatment) enrollment has been initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003661","json":"https://secwatch.observer/filing/0001171843-25-003661.json","markdown":"https://secwatch.observer/filing/0001171843-25-003661.md","text":"https://secwatch.observer/filing/0001171843-25-003661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/0001171843-25-003661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/f8k_060425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T23:57:23.483043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}